R. K. Thapa

Materials ScienceMedicinePhysics and Astronomy

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Data from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer”.

Data from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

(2023)10.1158/1078-0432.c.6531020

N/A

0DataRank · unranked

0 citations

Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, R. K. Thapa +13 more

Data from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

(2023)10.1158/1078-0432.c.6531020.v1

N/A

0DataRank · unranked

0 citations

Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, R. K. Thapa +13 more